A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2-locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling

被引：0
|
作者：
LeVee, Alexis Ann
Egelston, Colt A.
Yost, Susan Elaine
Frankel, Paul Henry
Lee, Keehoon
Ruel, Christopher
Schmolze, Daniel
Lee, Peter P.
Yeon, Christina Haeyoung
Yuan, Yuan
Waisman, James Ross
Pal, Sumanta Kumar
Mortimer, Joanne E.
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Translat Genom Res Inst TGen North, Flagstaff, AZ USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1038
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HR+/HER2-locally advanced or metastatic Breast Cancer "I am observing a high level of Patient Satisfaction"
    不详
    BREAST CARE, 2018, 13 (04) : 303 - 303
  • [2] HR+/HER2-locally advanced or metastatic Breast Cancer Ibrance® MyTherapy App: Digital Therapy Support with comprehensive Functions for Breast Cancer Patients
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 344 - 344
  • [3] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024,
  • [4] Lerociclib plus fulvestrant in patients with HR+/HER2-locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial
    Xu, Binghe
    Zhang, Qingyuan
    Luo, Yang
    Tong, Zhongsheng
    Sun, Tao
    Shan, Changping
    Liu, Xinlan
    Yao, Yumin
    Zhao, Bing
    Wang, Shusen
    Zeng, Xiaohua
    Hu, Changlu
    Yan, Xi
    Wang, Xiaojia
    Jia, Hongyan
    Chen, Zhendong
    Qiu, Fuming
    Wu, Xinhong
    Zhang, Deyong
    Li, Tong
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [5] A phase II study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2-locally advanced breast cancer
    Wu, J.
    Shao, Q.
    Pan, X.
    Zhou, W.
    Wang, Y.
    Zhang, N.
    Zhou, X.
    Li, W.
    Xu, F.
    Zeng, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S328 - S328
  • [6] First-line treatment patterns in HR+/HER2-locally advanced or metastatic breast cancer in Europe
    Lewis, K.
    Kurosky, S.
    Last, M.
    Mitra, D.
    Lambert, A.
    Mahtani, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S371 - S372
  • [7] Real-world safety and effectiveness of ribociclib in Korean patients with HR+/HER2-locally advanced or metastatic breast cancer
    Kim, J. H.
    Chang, M-C.
    Kim, T-H.
    Seo, J. H.
    Kim, J-J.
    Won, H. S.
    Seong, M-K.
    Kang, Y.
    Lee, Y.
    Lee, K-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1419 - S1420
  • [8] LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2-locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy
    Xu, Binghe
    Zhang, Qingyuan
    Luo, Yang
    Tong, Zhongsheng
    Sun, Tao
    Shan, Changping
    Liu, Xinlan
    Yao, Yumin
    Zhao, Bing
    Wang, Shusen
    Zeng, Xiaohua
    Hu, Changlu
    Yan, Xi
    Wang, Xiaojia
    Jia, Hongyan
    Chen, Zhendong
    Qiu, Fuming
    Wu, Xinhong
    Zhang, Deyong
    Li, Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A single- arm Phase II clinical study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2-locally advanced breast cancer
    Shao, Qing
    Wu, Jing
    Zhang, Ningning
    Zeng, Xiaohua
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Phase II trial of palbociclib plus endocrine therapy followed by combination of pembrolizumab, palbociclib and endocrine therapy in patients with hormone receptor positive metastatic breast cancer
    Yuan, Yuan
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Schmolze, Daniel
    Stewart, Daphne
    Waisman, James
    Yap, Kelly
    Mortimer, Joanne
    Tank, Niki
    CANCER RESEARCH, 2023, 83 (05)
12345